Isosorbide mononitrate sustained-release capsules (Ⅰ)

Isosorbide mononitrate (ISMN) is the main biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its main pharmacological action is to relax vascular smooth muscle. ISMN releases nitric oxide (NO). NO is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby relaxing vascular smooth muscle, dilating peripheral arteries and veins, and having a stronger dilating effect on veins. Venous dilation causes blood to remain in the periphery, reducing the amount of blood returning to the heart, and reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload). Coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption, increase oxygen supply, and relieve angina pectoris. Carcinogenicity and mutagenicity were not observed in animal experiments.

Ingredients: The main ingredient of this product is isosorbide mononitrate, chemical name: 1,4:3,6-dianhydro-D-sorbitol-5-nitrate.

This product is a capsule, and the contents are white powder.

Used to prevent angina pectoris; treat persistent angina pectoris after myocardial infarction and coronary heart disease; used in combination with digitalis or diuretics to treat chronic congestive heart failure.

Oral administration: 10-20 mg at a time, twice a day, orally.

1. Nitrate-induced vasodilatory headache may occur in the early stage of medication, but the symptoms usually disappear after taking it for several days. 2. Facial flushing, dizziness, orthostatic hypotension and reflex tachycardia may also occur. 3. Occasionally, blood pressure may drop significantly, bradycardia, angina pectoris may worsen and syncope may occur.

1. Contraindicated in patients with acute circulatory failure (shock, circulatory collapse). 2. Contraindicated in patients with severe hypotension (systolic blood pressure 90 mmHg). 3. Contraindicated in patients with acute myocardial infarction and low filling pressure (unless under continuous hemodynamic monitoring). 4. Contraindicated in patients with hypertrophic obstructive cardiomyopathy, constrictive pericarditis or cardiac tamponade. 5. Contraindicated in patients with severe anemia, glaucoma, and increased intracranial pressure. 6. Contraindicated in patients allergic to nitro compounds.

Precautions for children: The safety and effectiveness of this product in children have not been established. Precautions for pregnancy and lactation: Women in the first 3 months of pregnancy are prohibited from using this product, and lactating women should use this product with caution. Precautions for the elderly: No effect.

Combination with other vasodilators, calcium antagonists, beta-receptor blockers, antihypertensives, tricyclic antidepressants and alcohol can enhance the blood pressure lowering effect of this class of drugs.

Keep in a light-proof and airtight container. The validity period is tentatively set at 1.5 years.

40mg

48 months

Shanghai Xudong Haipu Pharmaceutical Co., Ltd.

• Founded in:

  1993-01-06

• Address:

  No. 879, Jinhu Road, China (Shanghai) Pilot Free Trade Zone

• Tax NO.:

  91310115607203592Y

• Registered Funds:

  $9,478,623

• Website:

  Log in to view

• Email:

  Log in to view